Literature DB >> 16512781

Molecular profiling of cervical neoplasia.

Cara M Martin1, Katharine Astbury, John J O'Leary.   

Abstract

Cervical cancer, a potentially preventable disease, remains the second most common malignancy in women worldwide. Human papillomavirus is the single most important etiological agent in cervical cancer, contributing to neoplastic progression through the action of viral oncoproteins, mainly E6 and E7, which interfere with critical cell cycle pathways, p53 and retinoblastoma. However, evidence suggests that human papillomavirus infection alone is insufficient to induce malignant changes and that other host genetic variations are important in the development of cervical cancer. This article will discuss the latest molecular profiling techniques available and review the published literature relating to their role in the diagnosis and management of cervical dysplasia and cancer. It is hoped that these techniques will allow the detection of novel biomarkers at DNA, RNA, microRNA and protein levels, which may ultimately play a role in facilitating early disease diagnosis and in predicting response to therapies, thus allowing the development of personalized treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16512781     DOI: 10.1586/14737159.6.2.217

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  13 in total

1.  Identification of miR-23a as a novel microRNA normalizer for relative quantification in human uterine cervical tissues.

Authors:  Yuanming Shen; Yang Li; Feng Ye; Fenfen Wang; Xiaoyun Wan; Weiguo Lu; Xing Xie
Journal:  Exp Mol Med       Date:  2011-06-30       Impact factor: 8.718

2.  Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma.

Authors:  Teresa Warchoł; Lukasz Kruszyna; Margarita Lianeri; Andrzej Roszak; Paweł P Jagodziński
Journal:  Pathol Oncol Res       Date:  2010-08-03       Impact factor: 3.201

3.  A simple array platform for microRNA analysis and its application in mouse tissues.

Authors:  Xiaoqing Tang; Jozsef Gal; Xun Zhuang; Wangxia Wang; Haining Zhu; Guiliang Tang
Journal:  RNA       Date:  2007-08-03       Impact factor: 4.942

4.  S100A8/A9 induces apoptosis and inhibits metastasis of CasKi human cervical cancer cells.

Authors:  Fengjin Qin; Yao Song; Zijian Li; Ling Zhao; Youyi Zhang; Li Geng
Journal:  Pathol Oncol Res       Date:  2009-12-03       Impact factor: 3.201

5.  The expression of Mcl-1 in human cervical cancer and its clinical significance.

Authors:  Ting Zhang; Chun Zhao; Liang Luo; Hua Zhao; Jing Cheng; Fei Xu
Journal:  Med Oncol       Date:  2011-06-15       Impact factor: 3.064

6.  Novel epigenetic changes in CDKN2A are associated with progression of cervical intraepithelial neoplasia.

Authors:  N Ari Wijetunga; Thomas J Belbin; Robert D Burk; Kathleen Whitney; Maria Abadi; John M Greally; Mark H Einstein; Nicolas F Schlecht
Journal:  Gynecol Oncol       Date:  2016-07-09       Impact factor: 5.482

7.  [Over-expression of miR-519d alters gene expression profiles of cervical cancer SiHa cells].

Authors:  Ye Zeng; Jie Liu; Zhichao Cheng; Sirong Zheng; Hanrong Zhang; Jueyu Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

8.  MicroRNA-10b inhibits proliferation, migration and invasion in cervical cancer cells via direct targeting of insulin-like growth factor-1 receptor.

Authors:  Ren Hou; Daixian Wang; Jian Lu
Journal:  Oncol Lett       Date:  2017-04-13       Impact factor: 2.967

9.  Stabilization of mismatch repair gene PMS2 by glycogen synthase kinase 3beta is implicated in the treatment of cervical carcinoma.

Authors:  Yuan Zhang; Yi Min Shu; Shu Fang Wang; Bang Hong Da; Ze Hua Wang; Hua Bin Li
Journal:  BMC Cancer       Date:  2010-02-23       Impact factor: 4.430

Review 10.  Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers.

Authors:  Cara M Martin; Louise Kehoe; Cathy O Spillane; John J O'Leary
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.